Tirzepatide Therapy Innovation Officially Launched in Indonesia for Type 2 Diabetes and Obesity
A new evidence-based therapy option for the management of type 2 diabetes mellitus and obesity is now officially available in Indonesia through the introduction of tirzepatide. This medical innovation is the first dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist of its class, which is expected to address the increasing metabolic health challenges in the country.
Type 2 diabetes mellitus and obesity are two closely interrelated conditions. According to data from the International Diabetes Federation (IDF) Diabetes Atlas 2025, it is estimated that 20.4 million adults in Indonesia are living with diabetes. This figure is projected to surge to 28.6 million by 2050.
On the other hand, the 2023 Indonesian Health Survey (SKI) noted that the prevalence of adult obesity has reached 23.4%, a significant increase that heightens the risk of serious complications such as cardiovascular disease and chronic kidney disease.
PT Anugerah Pharmindo Lestari (APL), a Zuellig Pharma company, announced the arrival of tirzepatide. Christophe Piganiol, President Director of APL, stated that this move is part of the company’s efforts to bring impactful health innovations to the Indonesian people.
“The arrival of tirzepatide is an important step in our efforts to provide impactful health innovation for the Indonesian community and to ensure more patients can gain access to the right therapy,” said Christophe Piganiol.
The presence of tirzepatide in the domestic market is also supported by an efficient regulatory process. Through a fast-track evaluation pathway from the Indonesian Food and Drug Authority (BPOM), this therapy can be accessed earlier by patients in need. APL is committed to working with medical professional organisations and healthcare workers to ensure that the education and distribution of this therapy proceed optimally.
With a dual mechanism of action targeting GIP and GLP-1 receptors, tirzetteide offers a more comprehensive approach to managing blood sugar levels while simultaneously assisting in weight management for obese patients.
The introduction of this innovation is expected to improve the quality of life for patients and reduce the national health burden caused by non-communicable diseases in the future.
Source: jawawa.id (https://jawawa.id/newsitem/tirzepatide-therapy-innovation-officially-launched-in-indonesia-for-type-2-diabetes-and-obesity-1783248711)
Originally published by Media Indonesia (https://mediaindonesia.com/humaniora/907717/inovasi-terapi-tirzepatide-resmi-hadir-di-indonesia-untuk-diabetes-tipe-2-dan-obesitas), translated from Indonesian